U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07092748) titled 'A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors' on July 22.

Brief Summary: This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)

Study Start Date: July 15

Study Type: INTERVENTIONAL

Condition: Advanced Solid Cancers

Intervention: DRUG: HS387

HS387 tablets will be given orally

Recruitment Status: RECRUITING

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.

Disclaimer: Curated by HT ...